This multicenter prospective single-arm postmarketing clinical follow-up (PMCF) study evaluated the effectiveness and safety of B-Lite lightweight breast implants in genetically female patients undergoing bilateral primary breast augmentation. The prespecified primary endpoint was achieving at least a one bra-cup increase at 12 months. Secondary endpoints included quality of life (QoL) instruments (Body Esteem, Rosenberg self-esteem, shortened Tennessee, RAND SF-36), patient and surgeon satisfaction, and adverse events (AEs) such as capsular contracture (Baker III–IV), implant rupture, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and reoperation.
The study was a manufacturer-sponsored, prospective, single-arm multicenter PMCF trial. A total of 101 genetically female patients were enrolled for bilateral primary augmentation. Reported baseline demographics included a mean age of 32.7 ± 8.0 years and a mean body mass index (BMI) of 20.9 ± 1.8. The follow-up duration reported included outcomes through 3 to 5 years, with key outcomes summarized at 12 months and Kaplan-Meier estimates provided for longer-term reoperation risk.
Implants used in the study included both round and anatomical shapes and four surface/finishes: POLYsmoooth, POLYtxt, MESMO, or Microthane. Implant volumes ranged from 200 to 755 cc. All implants were placed via inframammary incisions using a standardized surgical technique across sites. The device design incorporates air-filled microspheres within silicone gel with the intent to reduce implant weight by up to 30% while maintaining volume and mechanical properties.
Safety monitoring captured occurrences of capsular contracture (Baker grade III–IV), rupture, BIA-ALCL, sensory changes, and other AEs. In this cohort, no cases of Baker III or IV capsular contracture, no ruptures, and no occurrences of BIA-ALCL were reported. The most frequently observed adverse event was transient sensory change, occurring in 8.9% of patients. Other adverse events were described as infrequent and largely related to the procedure itself. The abstract does not present a comprehensive listing of all minor AEs or their time courses beyond the summary provided.
Reoperation risk was estimated using Kaplan-Meier analysis. The reported cumulative reoperation risk was 6.9% at 1 year and 9.9% at 5 years. The abstract does not provide a breakdown of indications for reoperation or timing details for individual cases beyond these cumulative estimates.
Patient satisfaction averaged 98.6% across the cohort, with 0% patient regret reported. Surgeons reported being satisfied or very satisfied in 97% to 100% of cases. These high satisfaction rates are reported as study outcomes; the abstract does not supply the specific survey instruments or the distribution of satisfaction responses over time beyond the summary figures.
Quality of life instruments demonstrated durable benefit in specific domains. The study reports improvements in Body Esteem—sexual attractiveness and in Rosenberg self-esteem scores. RAND SF-36 composite scores remained stable over the follow-up period. The abstract also lists the shortened Tennessee instrument among measures collected, but detailed subscale scores, statistical testing, or exact numeric changes for each QoL instrument are not provided in the abstract.
In this prospective, multicenter PMCF cohort of 101 primary augmentation patients, B-Lite lightweight breast implants achieved the primary effectiveness endpoint in 92% (95% CI, 84%–97%) of patients at 12 months and demonstrated a favorable safety profile through 3 to 5 years of follow-up. No Baker III–IV capsular contracture, rupture, or BIA-ALCL cases were recorded; transient sensory changes were the most common AE (8.9%). Kaplan-Meier reoperation risk was 6.9% at 1 year and 9.9% at 5 years. Patient satisfaction was very high (98.6%) with no reported patient regret, and surgeons reported 97%–100% satisfaction. QoL outcomes indicated durable gains in body esteem and self-esteem while SF-36 scores remained stable.
Limitations and additional details such as full adverse event tables, indications for reoperation, site-level variation, comparisons with other implant types, and longer-term outcomes beyond the 3–5 year window were not reported in the abstract. The abstract identifies the study as Level of evidence 2.
This summary is based solely on the abstract content as provided. The full text would be needed for comprehensive safety tables, statistical methodology, and granular outcome data.